Hematopoietic stem cells in neonates: any differences between very preterm and term neonates?

Area of Science:

• Hematology
• Neonatology
• Regenerative Medicine

Background:

• Human full-term cord blood is a known source of hematopoietic stem and progenitor cells (HSPCs).
• Limited understanding exists regarding HSPC function in preterm neonates, despite interest in regenerative therapies.

Purpose of the Study:

• To investigate HSPC concentration and clonogenic capacity in preterm versus term cord blood.
• To determine the influence of perinatal factors on HSPC subsets.

Main Methods:

• Flow cytometry analyzed CD34+ HSPC subsets in 30 preterm and 30 term cord blood samples.
• Clonogenic assays assessed the proliferative potential of HSPCs, including subsets defined by CD133 and ALDH activity.

Main Results:

• Preterm cord blood showed significantly higher concentrations of CD34+ HSPCs and enhanced clonogenic capacity.
• Maternal age, gestational age, and white blood cell count influenced HSPC counts; gestational age impacted clonogenic potential.
• Isolated preterm HSPC subsets (CD34+/CD133+, CD34+/CD133-, ALDH(high)) exhibited greater clonogenic potential than term counterparts.

Conclusions:

• Preterm cord blood demonstrates superior HSPC concentration and clonogenic capacity compared to term cord blood.
• These findings support the potential use of HSPCs in autologous stem cell therapy for preterm neonates.